Working... Menu
Trial record 93 of 424 for:    Pregabalin

A Comparison of Pregabalin (Lyrica®) to Placebo in Pain Relief After Photorefractive Keratectomy (PRK) Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01097577
Recruitment Status : Completed
First Posted : April 1, 2010
Last Update Posted : June 22, 2010
Information provided by:
Wilford Hall Medical Center

Brief Summary:

Purpose: To compare the efficacy of pregabalin to placebo for postoperative pain control after photorefractive keratectomy.

Patients: Study subjects will be taken from a standard group of typical candidates for PRK surgery including active duty and DoD beneficiaries. Prior to being approached for the study, all patients will have had a previous desire for surgery and had a pre-operative evaluation indicating healthy ocular status.

Methods: Patients scheduled for PRK surgery will be briefed on the purpose of the study and invited to participate at the preoperative appointment. After the consent process, patients will be randomized in a 1:1 fashion to receive either oral pregabalin 75mg BID or placebo for pain control, in addition to the standard care treatment of as needed Percocet and tetracaine ophthalmic drops. Subjects will be evaluated daily for 4 days post-operatively for subjective pain assessment, adverse drug events and compliance, use of concomitant medications as well as monitoring of healing time. Quality of life will be measured at baseline and post-op day 2 when the peak of pain is anticipated. Analysis will be performed to detect an approximate 10% improvement in pain scores. Secondary outcomes will include measuring healing time, quality of life and use of rescue medications.

Condition or disease Intervention/treatment Phase
Postoperative Pain Drug: pregabalin Drug: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Comparison of Pregabalin (Lyrica®) to Placebo in Postoperative Pain Relief of Patients Status-post Photorefractive Keratectomy: A Double-masked Randomized Prospective Study
Study Start Date : March 2010
Actual Primary Completion Date : June 2010
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Pregabalin

Arm Intervention/treatment
Experimental: pregabalin Drug: pregabalin
1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.
Other Name: Lyrica

Placebo Comparator: lactose capsule Drug: Placebo
1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.

Primary Outcome Measures :
  1. Clinical Efficacy [ Time Frame: 5 days ]
    Determine if clinical efficacy is achieved with pregabalin administered prior to PRK and continued for 5 days. This will be evaluated using the short-form McGill pain questionnaire (SF-MPQ).

Secondary Outcome Measures :
  1. Clinical efficacy 2 [ Time Frame: 5 days ]
    Determine if there was a reduction in the need for use of rescue pain medications, Percocet and tetracaine, in those subjects who received pregabalin.

  2. Epithelial healing time [ Time Frame: 5 days or more ]
    Determine if there was a reduction in healing time associated with pregabalin as seen with daily slit-lamp observation.

  3. Quality of Life [ Time Frame: 5 days ]
    Determine if there was an improvement in the patient's functional health and well-being associated with pregabalin compared to standard of care as assessed by Brief Pain Inventory-short form (BPI-SF).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Healthy ocular status
  • Stable preoperative refractive anisometropia
  • Consented to the PRK surgical procedure

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Diagnosed with autoimmune disease or diabetes
  • Patients with a known adverse reaction or hypersensitivity to gabapentin or pregabalin
  • Patients only desiring PRK on one eye
  • Patients with history of drug use/abuse/addiction
  • Patients who are on chronic pain medications
  • Patients currently taking anti-epileptic, antidepressant and/or anti-psychotic medications
  • Patients with a history of suicidality
  • Patients with chronic renal insufficiency (defined as estimated creatinine clearance less than 30ml/min or Scr ≥ 2.0) 10) Patients who have experienced angioedema, or have heart failure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01097577

Layout table for location information
United States, Texas
Wilford Hall Medical Center - Refractive Surgery Center
Lackland AFB, Texas, United States, 78236
Sponsors and Collaborators
Wilford Hall Medical Center
Layout table for investigator information
Principal Investigator: Julie M Meek, PharmD Wilford Hall Medical Center
Study Chair: Charles Reilly, MD Wilford Hall Medical Center
Study Director: Margaret Bonnie Rosbolt, PharmD, CCRC Wilford Hall Medical Center

Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: Capt Julie Meek, Wilford Hall Medical Center, US Air Force Identifier: NCT01097577     History of Changes
Other Study ID Numbers: FWH20100004H
First Posted: April 1, 2010    Key Record Dates
Last Update Posted: June 22, 2010
Last Verified: June 2010

Keywords provided by Wilford Hall Medical Center:
photorefractive keratectomy
excimer laser
pain, postoperative

Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Neurologic Manifestations
Signs and Symptoms
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs